TCL 联合 MHSP65 疫苗接种可诱导小鼠抗肺癌免疫。
Vaccination with TCL plus MHSP65 induces anti-lung cancer immunity in mice.
机构信息
Department of Molecular Biology, Norman Bethune College of Medicine, Jilin University, 130021, Changchun, China.
出版信息
Cancer Immunol Immunother. 2010 Jun;59(6):899-908. doi: 10.1007/s00262-010-0816-2. Epub 2010 Jan 20.
Abstract
To develop effective anti-lung cancer vaccines, we directly mixed mycobacterial heat shock protein 65 (MHSP65) and tumor cell lysate (TCL) from Lewis lung cancer cells in vitro and tested its efficacy on stimulating anti-tumor immunity. Our results showed that MHSP65-TCL immunization significantly inhibited the growth of lung cancer in mice and prolonged the survival of lung cancer bearing mice. In vivo and in vitro data suggest that MHSP65-TCL could induce specific CTL responses and non-specific immunity, both of which could contribute to the tumor inhibition. Thus, this report provides an easy approach to prepare an efficient TCL based tumor vaccine.
摘要
为了开发有效的肺癌疫苗，我们在体外直接混合分枝杆菌热休克蛋白 65（MHSP65）和来自 Lewis 肺癌细胞的肿瘤细胞裂解物（TCL），并测试其刺激抗肿瘤免疫的功效。我们的结果表明，MHSP65-TCL 免疫接种显著抑制了肺癌在小鼠中的生长，并延长了肺癌荷瘤小鼠的生存时间。体内和体外数据表明，MHSP65-TCL 可以诱导特异性 CTL 反应和非特异性免疫，两者都有助于肿瘤抑制。因此，本报告提供了一种制备高效 TCL 基础肿瘤疫苗的简便方法。
相似文献
1
Vaccination with TCL plus MHSP65 induces anti-lung cancer immunity in mice.TCL 联合 MHSP65 疫苗接种可诱导小鼠抗肺癌免疫。
Cancer Immunol Immunother. 2010 Jun;59(6):899-908. doi: 10.1007/s00262-010-0816-2. Epub 2010 Jan 20.
2
Vaccination with FasL-/TCL plus MHSP65 induces improved anti-lung cancer immunity in mice.FasL-/TCL 联合 MHSP65 疫苗接种可诱导小鼠产生更好的抗肺癌免疫。
Int Immunopharmacol. 2018 Feb;55:306-311. doi: 10.1016/j.intimp.2017.12.029. Epub 2018 Jan 5.
3
[Effect of MHSP65-TCL anti-melanoma vaccine on the activity of immunocytes].[MHSP65-TCL抗黑色素瘤疫苗对免疫细胞活性的影响]
Nan Fang Yi Ke Da Xue Xue Bao. 2013 Nov;33(11):1673-7.
4
Antitumor activity of mHSP65-TTL enhanced by administration of low dose cyclophosphamide in pancreatic cancer-bearing mice.低剂量环磷酰胺给药增强荷胰腺癌小鼠体内mHSP65-TTL的抗肿瘤活性。
Int Immunopharmacol. 2015 Jul;27(1):95-103. doi: 10.1016/j.intimp.2015.04.014. Epub 2015 Apr 20.
5
MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice.MF59 联合 CpG ODN 作为重组 HSP65-MUC1 的有效佐剂，在小鼠中诱导抗 MUC1+肿瘤免疫。
Int Immunopharmacol. 2012 Aug;13(4):408-16. doi: 10.1016/j.intimp.2012.05.003. Epub 2012 May 14.
6
Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model.在小鼠肺癌模型中，细菌幽灵作为基于同基因肿瘤细胞裂解物的抗癌疫苗接种的佐剂。
Oncol Rep. 2017 Jan;37(1):171-178. doi: 10.3892/or.2016.5252. Epub 2016 Nov 16.
7
Assessment of in vivo anti-tumor activity of human umbilical vein endothelial cell vaccines prepared by various antigen forms.评估不同抗原形式制备的人脐静脉内皮细胞疫苗的体内抗肿瘤活性。
Eur J Pharm Sci. 2018 Mar 1;114:228-237. doi: 10.1016/j.ejps.2017.12.020. Epub 2017 Dec 24.
8
Anti-glioma effect of intracranial vaccination with tumor cell lysate plus flagellin in mice.颅内接种肿瘤细胞裂解物加鞭毛蛋白对小鼠的抗胶质瘤作用。
Vaccine. 2018 Dec 18;36(52):8148-8157. doi: 10.1016/j.vaccine.2018.04.053. Epub 2018 Nov 16.
9
Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects.使用共表达GM-CSF和IL-18的经辐照肺癌细胞疫苗进行细胞免疫治疗可诱导显著的抗肿瘤作用。
BMC Cancer. 2014 Jan 29;14:48. doi: 10.1186/1471-2407-14-48.
10
Co-administration of rIpaB domain of Shigella with rGroEL of S. Typhi enhances the immune responses and protective efficacy against Shigella infection.将志贺氏菌的rIpaB结构域与伤寒沙门氏菌的rGroEL共同给药可增强免疫反应以及针对志贺氏菌感染的保护效力。
Cell Mol Immunol. 2015 Nov;12(6):757-67. doi: 10.1038/cmi.2014.86. Epub 2015 Feb 2.
引用本文的文献
1
Different Triple-Negative Breast Cancer Tumor Cell Lysates (TCLs) Induce Discrepant Anti-Tumor Immunity by PD1/PDL-1 Interaction.不同三阴性乳腺癌肿瘤细胞裂解物（TCL）通过 PD1/PDL-1 相互作用诱导不同的抗肿瘤免疫。
Med Sci Monit. 2019 Jan 17;25:500-515. doi: 10.12659/MSM.911689.
2
Validating the pivotal role of the immune system in low-dose radiation-induced tumor inhibition in Lewis lung cancer-bearing mice.验证免疫系统在低剂量辐射诱导的 Lewis 肺癌荷瘤小鼠肿瘤抑制中的关键作用。
Cancer Med. 2018 Apr;7(4):1338-1348. doi: 10.1002/cam4.1344. Epub 2018 Feb 25.
3
Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.皮下免疫原性自体肿瘤裂解物免疫治疗可提高小鼠脑胶质瘤的存活率。
Sci Rep. 2017 Oct 24;7(1):13902. doi: 10.1038/s41598-017-12584-0.
4
Tumor cell lysate induces the immunosuppression and apoptosis of mouse immunocytes.肿瘤细胞裂解物诱导小鼠免疫细胞的免疫抑制和凋亡。
Mol Med Rep. 2014 Dec;10(6):2827-34. doi: 10.3892/mmr.2014.2606. Epub 2014 Oct 2.
5
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials.同种异体肿瘤细胞疫苗：临床试验中的前景与局限
Hum Vaccin Immunother. 2014;10(1):52-63. doi: 10.4161/hv.26568. Epub 2013 Sep 24.
6
MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice.MF59 联合 CpG ODN 作为重组 HSP65-MUC1 的有效佐剂，在小鼠中诱导抗 MUC1+肿瘤免疫。
Int Immunopharmacol. 2012 Aug;13(4):408-16. doi: 10.1016/j.intimp.2012.05.003. Epub 2012 May 14.
本文引用的文献
1
[Immunotherapy for cancer--modern immunologic strategies in oncology].癌症免疫疗法——肿瘤学中的现代免疫策略
Dtsch Med Wochenschr. 2008 Oct;133(41):2105-8. doi: 10.1055/s-0028-1091251. Epub 2008 Oct 1.
2
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.辅助性自体治疗性疫苗（HSPPC-96；维特司班）对比单纯观察用于肾细胞癌肾切除术后复发高危患者：一项多中心、开放标签、随机III期试验
Lancet. 2008 Jul 12;372(9633):145-154. doi: 10.1016/S0140-6736(08)60697-2. Epub 2008 Jul 3.
3
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.自体肿瘤源性热休克蛋白gp96肽复合物疫苗vitespen与医生选择的IV期黑色素瘤治疗方案的III期比较：C-100-21研究组
J Clin Oncol. 2008 Feb 20;26(6):955-62. doi: 10.1200/JCO.2007.11.9941.
4
Heat shock treatment of tumor lysate-pulsed dendritic cells enhances their capacity to elicit antitumor T cell responses against medullary thyroid carcinoma.肿瘤裂解物脉冲树突状细胞的热休克处理增强了它们引发针对甲状腺髓样癌的抗肿瘤T细胞反应的能力。
J Clin Endocrinol Metab. 2006 Nov;91(11):4571-7. doi: 10.1210/jc.2006-0971. Epub 2006 Sep 5.
5
Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity.热休克融合蛋白可诱导特异性和非特异性抗肿瘤免疫。
Eur J Immunol. 2006 May;36(5):1324-36. doi: 10.1002/eji.200535490.
6
Vaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma.含肿瘤细胞裂解物的融合脂质体对小鼠B16BL6黑色素瘤的疫苗效力
Biol Pharm Bull. 2006 Jan;29(1):100-4. doi: 10.1248/bpb.29.100.
7
Chaperone-rich cell lysates, immune activation and tumor vaccination.富含伴侣蛋白的细胞裂解物、免疫激活与肿瘤疫苗接种
Cancer Immunol Immunother. 2006 Mar;55(3):329-38. doi: 10.1007/s00262-005-0694-1. Epub 2005 May 11.
8
Targeting the innate immune response with improved vaccine adjuvants.用改良疫苗佐剂靶向先天免疫反应。
Nat Med. 2005 Apr;11(4 Suppl):S63-8. doi: 10.1038/nm1210.
9
CD69 is an immunoregulatory molecule induced following activation.CD69是一种在激活后诱导产生的免疫调节分子。
Trends Immunol. 2005 Mar;26(3):136-40. doi: 10.1016/j.it.2004.12.006.
10
Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.使用同种异体黑色素瘤肿瘤细胞裂解物疫苗Melacine的临床试验结果。
Semin Cancer Biol. 2003 Dec;13(6):409-15. doi: 10.1016/j.semcancer.2003.09.004.
Zotero 插件